• Economy
  • Politics
  • Society
  • Securities
  • Real estate
  • Culture
  • Entertainment
  • Sports
  • Opinion
Economy Corporation Pharma & Bio
Society Politics IT·Science
Securities Real Estate Global
Opinion Entertainment Sports Culture
Video Auto in Golf in
PHARM EDAILY Market in TheBeLT
Corporation
Lifestyle

"From Efficacy Failures to Controversy Over Internal Analysis"... Kolon TissueGene's U.S. Phase 3 Trial Objectivity Under Scrutiny

Kolon TissueGene CI (Photo courtesy of Kolon TissueGene) Kolon TissueGene’s TG-C, a cell-gene therapy for osteoarthritis, failed to demonstrate efficacy in the first topline results from its U.S. …
  • 2026-07-21 10:01:03
  • SONG YOUNG-DOO
Electronics

SamsungElectronics Wins Daesang for Eighth Consecutive Year, Led by AI Home Appliances

SamsungElectronics has won the “Daesang” for the eighth consecutive year, led by its home appliances featuring AI-based energy-saving technology. A wide range of AI appliances—including air conditione…
  • 2026-07-21 10:00:04
  • JAEMIN SONG
Lifestyle

VIVOZON PHARMACEUTICAL Launches “Lara Pang Tablets,” a Tablet-Form Bowel Cleansing Agent Designed for Ease of Use

VIVOZON PHARMACEUTICAL(082800)announced on the 21st that it will launch “Lalafang,” a tablet-form bowel preparation.Lalapang Tablets received marketing authorization from the Ministry of Food and Drug…
  • 2026-07-21 09:43:01
  • NA EUN-KYUNG
Lifestyle

National Cigarette Brand ‘Dis’ Now Imported… KT&G Corporation Shifts Production to the U.S.

KT&G Corporation is manufacturing its flagship cigarette brands, “THIS” and “THIS Plus,” in the United States and importing them into South Korea. Including “Hogshead,” which was launched last year, t…
  • 2026-07-21 09:01:18
  • SIN SOO-JUNG
Lifestyle

BARREL Co., Ltd. Launches Full-Scale Distribution Business in China… Opens Official Tmall Store

The water sports brand BARREL Co., Ltd.(267790)has shipped its first batch of products as part of its China distribution business and launched local online sales. In September, the company plans to in…
  • 2026-07-21 09:00:13
  • Kim Ji-woo
Lifestyle

Celltrion and Samsung, Not SMEs, Benefit from Biosimilar Phase 3 Exemption... Why?

With the official announcement of the Phase 3 clinical trial exemption for biosimilars, biosimilar companies are busy crunching the numbers. On the 14th, South Korea’s Ministry of Food and Drug Safety…
  • 2026-07-21 08:36:02
  • SONG YOUNG-DOO
Lifestyle

"Banana Milk and Ramen by the Sea"... GS25 Sees 136.9% Increase in Sales to Foreigners at Coastal Stores

As the summer vacation season kicks off, convenience store sales have surged significantly amid a rise in foreign tourists visiting coastal areas. Foreign tourists are purchasing items at GS25. (Ph…
  • 2026-07-21 08:35:27
  • Kim Ji-woo
Lifestyle

[Blue Ocean Veterinary Medical Devices] ① Jeong Byeong-gon, President of the Korea Veterinary Medicines Association: “Focus on ‘Animal-Specific’ Products Derived from Human Medicines”

As medical technology advances, the treatment of human diseases is rapidly evolving into the era of “personalized medicine” and “precision medicine.” This shift is now spreading to the field of veteri…
  • 2026-07-21 07:02:02
  • Kim Jinsoo
Lifestyle

'Largest Domestic M&A Deal': Samsung Bio, With Peptide Business, Solidifies Its Position as the World's No. 1 CDMO

SAMSUNG BIOLOGICS(207940)has signed the largest merger and acquisition (M&A) deal in South Korea’s pharmaceutical and biotech industry to produce peptide drugs, which are well known as ingredients in …
  • 2026-07-20 18:00:03
  • Kim Jinsoo
Lifestyle

Kolon TissueGene, Inc. Fails to Demonstrate Statistical Efficacy in Topline Results from U.S. Phase 3 Clinical Trial of ‘TG-C’ for Knee Osteoarthritis

“TG-C,” a cell-gene therapy candidate for knee osteoarthritis developed by Kolon TissueGene, Inc.(950160)—better known as Inbosa—failed to meet the primary efficacy endpoint in the topline results of …
  • 2026-07-20 17:30:16
  • YU JIN-HEE
prev 51 52 53 54 55 56 57 58 59 60 next

PHARM EDAILY

Shorts

EDAILY
  • 92, Tongil-ro, Jung-gu, Seoul, Korea
  • +82 2 3772 0114
  • webmaster@edaily.co.kr

※ This article has been translated using AI technology for the convenience of readers.

EDAILY provides this translation on an “as is” basis and makes no warranties, express or implied, regarding its accuracy, reliability, completeness, merchantability, or fitness for a particular purpose.
Due to the limitations of machine translation, the translated content may differ from the original Korean article. In the event of any discrepancy, the original Korean version shall prevail.
EDAILY shall not be liable for any loss or damage arising from the use of, or reliance on, the translated content.

© 2026 Copyrights by edaily. All Rights Reserved.
Korea
English